Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Dementia Clinical Trials

A listing of Dementia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (39) clinical trials

This study tests whether two investigational drugs called CAD106 and CNP520, administered separately, can delay and slow the progression of clinical symptoms associated with Alzheimer's Disease in participants at risk of developing clinical symptoms based on their age and genotype.   Other Details: https://clinicaltrials.gov/ct2/show/NCT02565511

Phase

A clinical research study is underway, evaluating an investigational study drug for adults with Parkinson's Disease who are experiencing a decline in memory and thinking.

Phase

Do something unforgettable today. Take part in research to help prevent Alzheimer’s.  

Phase

The purpose of this study is to test whether two investigational drugs called CAD106 and CNP520, administered separately, can slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their age and genotype.

Phase

The TauRX study is investigating the efficacy and safety of an investigational drug on symptoms of cognitive decline in individuals with mild  Alzheimer's disease, compared to a placebo. The study drug is a tablet which is taken by mouth twice per day. The study will last approximately 8 months.  

Phase

The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based on their age, APOE genotype and elevated amyloid.

Phase

Clinical research study of an investigational medication for the treatment of agitation in people with dementia of Alzheimer's type.  

Phase

This is a randomized, double-blind, placebo-controlled study that will assess the efficacy, safety, and tolerability of 2 dose levels of COR388 HCl in subjects with probable AD dementia according to the National Institute on Aging-Alzheimer’s Association (NIA-AA) criteria (McKhann 2011).  

Phase

Preclinical models suggest that riluzole, the active metabolite of BHV-4157, may protect from AD-related pathology and cognitive dysfunction. Titrated dose of BHV-4157 to 280 mg, or placebo, taken orally once daily. Duration of treatment is 48 weeks. There is also a screening period of up to 42 days; and a ...

Phase

A clinical research study evaluating an investigational drug for agitation associated with Alzheimer's disease.  Eligible patients will receive study-related care and treatment with either the study drug or the placebo for five weeks.  Compensation for time and travel may be available to patients and caregivers.  Visit www.ADVANCEClinicalStudy.com for more information. ...

Phase